Get the Stockscreener App
1.93
7.22%
0.13
Pre-market:
1.96
0.03
+1.55%
Pepgen Inc stock is traded at $1.93, with a volume of 902.25K.
It is up +7.22% in the last 24 hours and up +11.56% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
See More
Previous Close:
$1.80
Open:
$1.78
24h Volume:
902.25K
Relative Volume:
0.68
Market Cap:
$133.50M
Revenue:
-
Net Income/Loss:
$-89.66M
P/E Ratio:
-0.7974
EPS:
-2.4205
Net Cash Flow:
$-81.90M
1W Performance:
+22.15%
1M Performance:
+11.56%
6M Performance:
-57.49%
1Y Performance:
+34.03%
1-Day Range:
$1.73
$1.93
1-Week Range:
$1.52
$1.93
52-Week Range:
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.93 | 133.50M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Guggenheim | Buy |
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
Pictet Asset Management Holding SA Purchases 871,059 Shares of PepGen, Inc. $PEPG - MarketBeat
Stifel reiterates Buy on PepGen stock amid partial clinical hold - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - ChartMill
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - FinancialContent
[ARS] PepGen Inc. SEC Filing - Stock Titan
PepGen (NASDAQ: PEPG) details 2026 virtual meeting and auditor vote - Stock Titan
PepGen advances momentum with Palo Alto meeting on DM1 community engagement - Traders Union
PepGen shares slide 20% as FDA clinical hold overshadows earnings beat - MSN
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
PepGen Inc. tops EPS estimates by 29.3%, narrower loss no revenueReal Trader Insights - Cổng thông tin điện tử tỉnh Lào Cai
PepGen’s stock up 120% on DM1 trial success - MSN
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
PepGen (PEPG) Stock: Sentiment Overview (Bearish Sentiment) 2026-04-16Attention Driven Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
PEPG News | PEPGEN INC (NASDAQ:PEPG) - ChartMill
Biotech Firm PepGen Receives 'Moderate Buy' Rating from Analysts - National Today
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PepGen: Modest FREEDOM2 Efficacy, Regulatory Overhang, and Competitive Pressures Underscore Sell Rating - TipRanks
Signal Recap: Should I set a stop loss on PepGen Inc2026 Pullback Review & Technical Confirmation Alerts - baoquankhu1.vn
PepGen team joins Kansas City event to drive myotonic dystrophy research discussions - Traders Union
Rate Cut: Does PepGen Inc have declining or rising EPSAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
PepGen joins MyotonicStrong conference to present clinical progress - Traders Union
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
PEPG Q4 2025 Earnings: PepGen Inc. Beats EPS Estimates, No Revenue PostedHot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Retail Trends: Is PepGen Inc forming a breakout pattern2026 Chart Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Published on: 2026-04-07 21:04:49 - baoquankhu1.vn
PEPG.O Technical Analysis & Stock Price Forecast - Intellectia AI
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
PEPG Technical Analysis & Stock Price Forecast - Intellectia AI
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - National Today
Biopharma bites: PepGen's partial pause, Roche's Korea investment, plus Teva's financing - FirstWord Pharma
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Assay what? Eyes on Pepgen’s vim-sapping DM1 phase II - BioWorld MedTech
Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts - TipRanks
PEPG: FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation - TradingView — Track All Markets
MACD Signal: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAR2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):